{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:48:41Z","timestamp":1775659721027,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Abbott, Chicago, Illinois, USA"},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Comparative data on safety and efficacy of intra- and supra-annular self-expanding heart valves (THV) for transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis (AS) is scarce. The FIRE TAVI study compared procedural in-hospital and mid-term outcomes of the intra-annular Navitor THV and the supra-annular Evolut PRO THV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The retrospective, multicenter study enrolled patients with severe AS who underwent TAVI using Navitor or Evolut PRO. The primary composite safety endpoint included all-cause mortality, myocardial infarction, disabling stroke, life-threatening bleeding, major vascular complication, or acute kidney injury requiring dialysis until discharge. Secondary endpoints comprised pacemaker implantation, paravalvular leakage (PVL), and mean transvalvular gradient. Mortality was assessed 381\u2009\u00b1\u2009308\u00a0days after TAVI. Multivariable regression analysis was used for endpoint comparison of both THVs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Then, 269 patients after Navitor and 272 patients after Evolut PRO implantation were enrolled. There was no significant risk difference regarding the adjusted primary safety endpoint (OR 0.97 [95% CI 0.50\u20131.89]) and rate of pacemaker implantation (OR 1.13 [95% CI 0.67\u20131.90]). The pressure gradient was comparable between both groups (Navitor 7.0 [4.0\u201310.0] mmHg vs. Evolut PRO 6.0 [2.0\u201310.0] mmHg, mean difference\u2009\u2212\u20090.32 [95% CI -0.97\u20130.32]). Navitor showed a lower frequency of more than mild PVL (0.8% vs. 3.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032). Mortality was similar (HR 1.04 [95% CI 0.66\u20131.63]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The implantation of the intra-annular Navitor and the supra-annular Evolut PRO was safe, with severe adverse events occurring at similar rates until discharge. The risk of moderate or severe PVL was lower with Navitor; mid-term mortality was comparable in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                    <jats:p>The FIRE TAVI study compared patients with Navitor and Evolut platforms and showed that the implantation of the intra-annular self-expanding Navitor THV and the supra-annular self-expanding Evolut THV was safe and severe adverse events occurred with comparable frequency until discharge. Navitor patients presented a lower risk of moderate or severe PVL at discharge. The adjusted analysis included the following parameters: center, sex, age, BMI, Society of Thoracic Surgeons (STS) score, New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), mitral and tricuspid regurgitation, estimated glomerular filtration rate (eGFR), right bundle branch block (RBBB), coronary artery disease, prior stroke, chronic obstructive pulmonary disease, atrial fibrillation or flutter, peripheral artery disease, pulmonary hypertension, and transfemoral access. CI, confidence interval; HR, hazard ratio; OR, odds ratio; SEV, self-expanding valve; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart valve; PVL, paravalvular leakage. Illustration of the Evolut THV provided by Medtronic<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02910-w","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:53:34Z","timestamp":1775656414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early safety and efficacy of intra-annular versus supra-annular self-expanding transcatheter heart valves"],"prefix":"10.1007","author":[{"given":"Isabel","family":"Mattig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Romero Dorta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"K\u00f6sters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Katrin","family":"Fietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon H.","family":"S\u00fcndermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Unbehaun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Spethmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Stangl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Hindricks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenard","family":"Conradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1909-4329","authenticated-orcid":false,"given":"Henryk","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"9540","key":"2910_CR1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","volume":"368","author":"VT Nkomo","year":"2006","unstructured":"Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M (2006) Burden of valvular heart diseases: a population-based study. Lancet 368(9540):1005\u20131011","journal-title":"Lancet"},{"key":"2910_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezaf215","author":"T Doenst","year":"2025","unstructured":"Doenst T, Gregg AC, Kirov H, Di Franco A, Caldonazo T, Rahouma M (2025) Surgical vs. transcatheter treatment of aortic valve stenosis-a meta-analysis of low-risk randomized trials with completed 5-year follow-up. Eur J Cardiothorac Surg. https:\/\/doi.org\/10.1093\/ejcts\/ezaf215","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9","key":"2910_CR3","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jcin.2019.12.026","volume":"13","author":"M Abdel-Wahab","year":"2020","unstructured":"Abdel-Wahab M, Landt M, Neumann FJ, Massberg S, Frerker C, Kurz T et al (2020) 5-year outcomes after TAVR with balloon-expandable versus self-expanding valves: results from the CHOICE randomized clinical trial. JACC Cardiovasc Interv 13(9):1071\u201382","journal-title":"JACC Cardiovasc Interv"},{"issue":"10209","key":"2910_CR4","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/S0140-6736(19)32220-2","volume":"394","author":"J Lanz","year":"2019","unstructured":"Lanz J, Kim WK, Walther T, Burgdorf C, Mollmann H, Linke A et al (2019) Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. Lancet 394(10209):1619\u20131628","journal-title":"Lancet"},{"issue":"20","key":"2910_CR5","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/eurheartj\/ehaa036","volume":"41","author":"H Thiele","year":"2020","unstructured":"Thiele H, Kurz T, Feistritzer HJ, Stachel G, Hartung P, Eitel I et al (2020) Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. Eur Heart J 41(20):1890\u20139","journal-title":"Eur Heart J"},{"issue":"12","key":"2910_CR6","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jcin.2025.03.015","volume":"18","author":"S Cannata","year":"2025","unstructured":"Cannata S, Sultan I, Van Mieghem N, Giordano A, De Backer O, Byrne J et al (2025) Transcatheter aortic valve replacement with intra-annular self-expanding or balloon-expandable valves: the Multicenter International NAVULTRA Registry. JACC Cardiovasc Interv 18(12):1557\u20131568","journal-title":"JACC Cardiovasc Interv"},{"issue":"20","key":"2910_CR7","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jcin.2021.07.034","volume":"14","author":"M Akodad","year":"2021","unstructured":"Akodad M, Sellers S, Gulsin GS, Tzimas G, Landes U, Chatfield AG et al (2021) Leaflet and neoskirt height in transcatheter heart valves: implications for repeat procedures and coronary access. JACC Cardiovasc Interv 14(20):2298\u20132300","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"2910_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03397-3","volume":"23","author":"B Wang","year":"2023","unstructured":"Wang B, Mei Z, Ge X, Li Y, Zhou Q, Meng X et al (2023) Comparison of outcomes of self-expanding versus balloon-expandable valves for transcatheter aortic valve replacement: a meta-analysis of randomized and propensity-matched studies. BMC Cardiovasc Disord 23(1):382","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"2910_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.122.012294","volume":"15","author":"G Costa","year":"2022","unstructured":"Costa G, Barbanti M, Rosato S, Seccareccia F, Tarantini G, Fineschi M et al (2022) Real-world multiple comparison of transcatheter aortic valves: insights from the multicenter OBSERVANT II Study. Circ Cardiovasc Interv 15(12):e012294","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"2910_CR10","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.21037\/jtd-20-1700","volume":"12","author":"C Pellegrini","year":"2020","unstructured":"Pellegrini C, Rheude T, Michel J, Alvarez-Covarrubias HA, Wunsch S, Mayr NP et al (2020) Comparison of latest generation supra-annular and intra-annular self-expanding transcatheter heart valves. J Thorac Dis 12(11):6769\u201379","journal-title":"J Thorac Dis"},{"issue":"7","key":"2910_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al (2022) 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43(7):561\u2013632","journal-title":"Eur Heart J"},{"issue":"19","key":"2910_CR12","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/eurheartj\/ehaa799","volume":"42","author":"P Genereux","year":"2021","unstructured":"Varc-3 Writing C, Genereux P, Piazza N, Alu MC, Nazif T, Hahn RT et al (2021) Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J 42(19):1825\u20131857","journal-title":"Eur Heart J"},{"key":"2910_CR13","unstructured":"Edwards Lifesciences. Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA\u00a0Transcatheter Heart Valve System [Internet]. 2025 [cited 2025 Nov 1]. Available\u00a0from: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf14\/P140031S162C.pdf"},{"issue":"19","key":"2910_CR14","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D'Agostino Jr.","year":"1998","unstructured":"D\u2019Agostino RB Jr. (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17(19):2265\u20132281","journal-title":"Stat Med"},{"key":"2910_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/9781119013563","volume-title":"Statistical analysis with missing data","author":"RJARD Little","year":"2002","unstructured":"Little RJARD (2002) Statistical analysis with missing data, 2nd ed. Wiley & Sons, Inc., New Jersey","edition":"2nd ed"},{"key":"2910_CR16","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"2004","unstructured":"Rubin DB (2004) Multiple imputation for nonresponse in surveys. Wiley, New Jersey"},{"issue":"1","key":"2910_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.shj.2024.100334","volume":"9","author":"MP Sa","year":"2025","unstructured":"Sa MP, Ahmad D, Wang Y, Thoma F, Makani A, Kliner D et al (2025) Supra-annular versus intra-annular self-expanding valves in small aortic annulus: a propensity score-matched study. Struct Heart 9(1):100334","journal-title":"Struct Heart"},{"issue":"13","key":"2910_CR18","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.4244\/EIJ-D-24-00966","volume":"21","author":"M Yamamoto","year":"2025","unstructured":"Yamamoto M, Ryuzaki T, Hioki H, Kagase A, Shirai S, Ohno Y et al (2025) Intra- versus supra-annular self-expanding transcatheter heart valves in small aortic annuli. EuroIntervention 21(13):e749\u2013e757","journal-title":"EuroIntervention"},{"key":"2910_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14165890","author":"C Campanella","year":"2025","unstructured":"Campanella C, Kaiser K, Voss S, Burri M, Erlebach M, Puluca N et al (2025) A comparison of short-term clinical outcomes between the navitor and evolut transcatheter aortic valve prostheses. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14165890","journal-title":"J Clin Med"},{"issue":"18","key":"2910_CR20","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","volume":"380","author":"JJ Popma","year":"2019","unstructured":"Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O\u2019Hair D et al (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380(18):1706\u201315","journal-title":"N Engl J Med"},{"issue":"24","key":"2910_CR21","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.jcin.2018.09.001","volume":"11","author":"V Vilalta","year":"2018","unstructured":"Vilalta V, Asmarats L, Ferreira-Neto AN, Maes F, de Freitas Campos Guimaraes L, Couture T et al (2018) Incidence, clinical characteristics, and impact of acute coronary syndrome following transcatheter aortic valve replacement. JACC Cardiovasc Interv 11(24):2523\u201333","journal-title":"JACC Cardiovasc Interv"},{"issue":"21","key":"2910_CR22","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.jcin.2020.07.006","volume":"13","author":"M Barbanti","year":"2020","unstructured":"Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R et al (2020) Coronary cannulation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC Cardiovasc Interv 13(21):2542\u201355","journal-title":"JACC Cardiovasc Interv"},{"issue":"17","key":"2910_CR23","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2013.07.040","volume":"62","author":"HB Ribeiro","year":"2013","unstructured":"Ribeiro HB, Webb JG, Makkar RR, Cohen MG, Kapadia SR, Kodali S et al (2013) Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol 62(17):1552\u20131562","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2910_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jcin.2020.01.202","volume":"13","author":"T Rogers","year":"2020","unstructured":"Rogers T, Greenspun BC, Weissman G, Torguson R, Craig P, Shults C et al (2020) Feasibility of coronary access and aortic valve reintervention in low-risk TAVR patients. JACC Cardiovasc Interv 13(6):726\u201335","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"2910_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jcin.2022.11.018","volume":"16","author":"JM Khan","year":"2023","unstructured":"Khan JM, Kamioka N, Lisko JC, Perdoncin E, Zhang C, Maini A et al (2023) Coronary obstruction from TAVR in native aortic stenosis: development and validation of multivariate prediction model. JACC Cardiovasc Interv 16(4):415\u2013425","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"2910_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102055","volume":"4","author":"S Khera","year":"2025","unstructured":"Khera S, Zaid S, Krishnamoorthy P, Koshy AN, Gudibendi S, Berdan M et al (2025) Ideal navitor implant depth for Redo-TAVR feasibility and coronary access: a CT simulation study. JACC Adv 4(9):102055","journal-title":"JACC Adv"},{"issue":"9","key":"2910_CR27","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jcin.2025.02.026","volume":"18","author":"Y Kobari","year":"2025","unstructured":"Kobari Y, Khokhar AA, Lulic D, Kofoed KF, Fuchs A, Bieliauskas G et al (2025) Impact of transcatheter aortic valve design and implant strategy on Redo-TAVR feasibility: a CT-based analysis. JACC Cardiovasc Interv 18(9):1206\u20131208","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02910-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02910-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02910-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:53:37Z","timestamp":1775656417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02910-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":27,"alternative-id":["2910"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02910-w","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany (EA4\/126\/22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"ERD: advisory board, speaker\u2019s fees, and travel support from Edwards LifeSciences. AB: research funding and speaker\u2019s fees from Medtronic. LC: advisory board for Abbott, JenaValve, Medtronic, consultant for Edwards Lifesciences, BostonScientific, MicroInterventions, MicroPort, PiCardia, smartcanula sarl, VenusMedtech, 4\u2009C Medical. AS: Proctor for Abbott, travel compensation, and speaker\u2019s fee from Abbott. HD: advisory board, research support, and speaker\u2019s fees from Abbott and Edwards LifeSciences. The other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients were not involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Reporting patient and public involvement in research"}}]}}